- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Phosphodiesterase type 4 (PDE-4) Inhibitors
- Antibiotics
- Antihistamines
- Emollients
Atopic Dermatitis Treatment Market size was valued at 1513.2 Million in 2023 and is poised to grow at a CAGR of 9.7% during 2024-2030. Atopic dermatitis atopic eczema. is a type of inflammatory disease that is of unknown origin and usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen, and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure, and difficulties in the permeability of the skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including.
The atopic dermatitis treatment includes mainly steroid creams and moisturizers. Often, antibiotics are used when there is a skin infection. Diagnosis is done by physical examination and in some cases, biopsy is performed. Atopic Dermatitis Treatment aims to control inflammation and relieve itching. The atopic dermatitis treatment market growth is expected to grow at a steady state during the forecast period. Market players are focusing on research and development to discover new drugs to treat atopic dermatitis. Several global and regional players companies adopting strategies such as acquisitions, mergers, and partnering with other players to withstand the competition and grow their atopic dermatitis treatment market share.
Atopic Dermatitis Treatment Market Key Developments:
- In December 2016, Novartis acquired UK based Ziarco Group and expanded its R&D portfolio with once daily oral H4 receptor agonist, ZPL389, that is being developed for the treatment of atopic dermatitis. In addition, new classes of products are launched targeting atopic dermatitis other than the traditional classes such as corticosteroids. This gives the health care professionals to choose various alternatives.
In February 2017, Pfizer got FDA approval for Eucris, a non-steroidal topical phosphodiesterase-4 inhibitor that is used for treatment of mild to moderate atopic dermatitis.
The list of pharmaceutical companies, the products they offer for the treatment of atopic dermatitis, and the year of launch.
Sanofi: Dupixent (Dupilumab) - Launched in 2017.
Regeneron Pharmaceuticals: Dupixent (Dupilumab) - Launched in 2017.
Pfizer: Eucrisa (Crisaborole) - Launched in 2016.
Eli Lilly: Olumiant (Baricitinib) - Initially approved for rheumatoid arthritis in 2018, and received FDA approval for atopic dermatitis in 2021.
Incyte Corporation: Olumiant (Baricitinib) - Initially approved for rheumatoid arthritis in 2018, and received FDA approval for atopic dermatitis in 2021
Global Atopic Dermatitis Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9.7%
Largest Market
North America
Fastest Growing Market
North America
Atopic Dermatitis Treatment Market Dynamics
Global Atopic Eczema treatment market is driven by increased R&D funding to develop biologics and development of targeted therapies for atopic dermatitis. In addition increased incidence of atopic dermatitis, new product launches, and increased awareness about the symptoms of atopic dermatitis expected to further boost the market. However, availability of the generic drugs and high cost of dermatology drugs are expected to hamper the market during the forecast period.
North-America Got Significant Share
Atopic Dermatitis Treatment Market Regional Analysis
Geographically atopic dermatitis treatment market has been segmented into following regions Viz. North America, Latin America, Asia Pacific, Europe, and Middle East and Africa. North America dominates the market, expected to show notable growth rates owing to product launches, lifestyle changes, and early treatment adoption. According to the national eczema association in the U.S., 31.6 million people are living with eczema. Europe atopic dermatitis market is growing due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, availability of large patient pool and changing lifestyle.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Atopic Dermatitis Treatment Market Segmentation
By Drug type
By Route Administration
- Oral
- Topical
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Frequently Asked Questions
The Atopic Dermatitis Treatment Market size was valued at 1513.2 Million in 2023 and is poised to grow at a CAGR of 9.7% during 2024-2030
Pfizer Inc, Anacor Pharmaceutical Inc, Regeneron Pharmaceuticals, Inc, Sanofi S.A, Novartis AG
North America is the fastest-growing region for the Atopic Dermatitis Treatment Market
| 1.Executive Summary |
| 2.Global Atopic Dermatitis Treatment Market Introduction |
| 2.1.Global Atopic Dermatitis Treatment Market - Taxonomy |
| 2.2.Global Atopic Dermatitis Treatment Market - Definitions |
| 2.2.1.Drugs Type |
| 2.2.2.Route Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Atopic Dermatitis Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Atopic Dermatitis Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Atopic Dermatitis Treatment Market By Drugs Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Corticosteroids |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Calcineurin Inhibitors |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immunosuppressants |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Phosphodiesterase type 4 (PDE-4) Inhibitors |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Antibiotics |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Antihistamines |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Emollients |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Atopic Dermatitis Treatment Market By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Topical |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Parenteral |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Atopic Dermatitis Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Atopic Dermatitis Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Atopic Dermatitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drugs Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Corticosteroids |
| 9.1.2.Calcineurin Inhibitors |
| 9.1.3.Immunosuppressants |
| 9.1.4.Phosphodiesterase type 4 (PDE-4) Inhibitors |
| 9.1.5.Antibiotics |
| 9.1.6.Antihistamines |
| 9.1.7.Emollients |
| 9.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Topical |
| 9.2.3.Parenteral |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Atopic Dermatitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drugs Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Corticosteroids |
| 10.1.2.Calcineurin Inhibitors |
| 10.1.3.Immunosuppressants |
| 10.1.4.Phosphodiesterase type 4 (PDE-4) Inhibitors |
| 10.1.5.Antibiotics |
| 10.1.6.Antihistamines |
| 10.1.7.Emollients |
| 10.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Topical |
| 10.2.3.Parenteral |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 10.4.7. |
| 11.Asia Pacific (APAC) Atopic Dermatitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drugs Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Corticosteroids |
| 11.1.2.Calcineurin Inhibitors |
| 11.1.3.Immunosuppressants |
| 11.1.4.Phosphodiesterase type 4 (PDE-4) Inhibitors |
| 11.1.5.Antibiotics |
| 11.1.6.Antihistamines |
| 11.1.7.Emollients |
| 11.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Topical |
| 11.2.3.Parenteral |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Atopic Dermatitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drugs Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Corticosteroids |
| 12.1.2.Calcineurin Inhibitors |
| 12.1.3.Immunosuppressants |
| 12.1.4.Phosphodiesterase type 4 (PDE-4) Inhibitors |
| 12.1.5.Antibiotics |
| 12.1.6.Antihistamines |
| 12.1.7.Emollients |
| 12.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Topical |
| 12.2.3.Parenteral |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Atopic Dermatitis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drugs Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Corticosteroids |
| 13.1.2.Calcineurin Inhibitors |
| 13.1.3.Immunosuppressants |
| 13.1.4.Phosphodiesterase type 4 (PDE-4) Inhibitors |
| 13.1.5.Antibiotics |
| 13.1.6.Antihistamines |
| 13.1.7.Emollients |
| 13.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Topical |
| 13.2.3.Parenteral |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Leo Pharma A/S (Denmark), |
| 14.2.2.Velite Pharmaceutical (India), |
| 14.2.3.Nestlé S.A. (Galderma SA) (Switzerland), |
| 14.2.4.Pfizer Inc. (U.S.), |
| 14.2.5.Anacor Pharmaceutical Inc. (U.S.), |
| 14.2.6.Regeneron Pharmaceuticals, Inc. (U.S), |
| 14.2.7.Sanofi S.A. (France), |
| 14.2.8.Novartis AG (Switzerland), |
| 14.2.9.Bayer AG (Germany), |
| 14.2.10.Mylan N.V. (Meda Pharmaceuticals) (U.S.), |
| 14.2.11.Bristol-Myers Squibb (BMS) (U.S), and |
| 14.2.12.Allergan Plc. (Ireland) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Leo Pharma A/S (Denmark),
- Velite Pharmaceutical (India),
- Nestlé S.A. (Galderma SA) (Switzerland),
- Pfizer Inc. (U.S.),
- Anacor Pharmaceutical Inc. (U.S.),
- Regeneron Pharmaceuticals, Inc. (U.S),
- Sanofi S.A. (France),
- Novartis AG (Switzerland),
- Bayer AG (Germany),
- Mylan N.V. (Meda Pharmaceuticals) (U.S.),
- Bristol-Myers Squibb (BMS) (U.S), and
- Allergan Plc. (Ireland)